Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire

Lewis, Ronald W.; Bennett, Carol J.; Borkon, William D.; Boykin, William H.; Althof, Stanley E.; Stecher, Vera J.; Siegel, Richard L.

doi:10.1016/s0090-4295(01)00945-1

Cited by 99 publications

(71 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…14 The current analysis also showed that partners were more satisfied with sildenafil than with IC PGE 1 and that there was a high degree of correlation between patient and partner satisfaction, confirming earlier reports. 22,23 In our study, 42% of patients had organic ED, 34% had psychogenic ED, and 24% had mixed ED, which is comparable to previous studies that also showed sildenafil to be effective in men with ED of organic, psychogenic, or mixed causes. 4,5 Organic causes of ED tend to be associated with greater ED severity, and patients with less severe ED, such as psychogenic ED, tend to have better treatment outcomes.…”

Section: Discussionsupporting

confidence: 87%

Treatment satisfaction in patients with erectile dysfunction switching from prostaglandin E1 intracavernosal injection therapy to oral sildenafil citrate

Montorsi

Sweeney

et al. 2003

Int J Impot Res

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 87%

Treatment satisfaction in patients with erectile dysfunction switching from prostaglandin E1 intracavernosal injection therapy to oral sildenafil citrate

Montorsi

Sweeney

et al. 2003

Int J Impot Res

View full text Add to dashboard Cite

“…Sildenafil-treated patients had a median EDITS score of 74.6±12.8, which was significantly higher than the median score of 30.6 ± 4.4 for placebo patients (P ¼ 0.001). Overall, the proportion of patients satisfied with treatment (defined as final EDITS score 450) 23 was 70% for the sildenafil-treated group and 13% for the placebo-treated group (P ¼ 0.001) ( Table 3). Patients treated with sildenafil also experienced statistically significant clinical benefits over placebo on the mean EDITS for partners (Table 5, P ¼ 0.01) and individual EDITS questions, including overall satisfaction (P ¼ 0.01), partner satisfaction (P ¼ 0.01) and likelihood of continuing treatment (P ¼ 0.01).…”

Section: Secondary Efficacy Measuresmentioning

confidence: 99%

Safety and efficacy of sildenafil citrate in the treatment of Parkinson-emergent erectile dysfunction: a double-blind, placebo-controlled, randomized study

Safarinejad¹,

Taghva

Shekarchi

et al. 2010

Int J Impot Res

View full text Add to dashboard Cite

Parkinson's disease (PD) is one of the most commonly occurring neurodegenerative disorders, with lifetime incidence between 1 and 2% among people older than 65 years. ED is one of the more disabling and poorly addressed aspects of PD. The purpose of this study was to assess the efficacy and safety of sildenafil citrate in Parkinson-emergent ED. Sexual function of participants was assessed using responses to the 15-question International Index of Erectile Function (IIEF), Sexual Encounter Profile (SEP) diary questions 2 and 3, Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) questionnaire and a Global Efficacy Question 'Has the treatment you have been taking over the study period improved your erections?' This randomized, double-blind, placebocontrolled study, comprised a screening period of at least 1 month, a placebo-lead in period of 1 week and treatment period. Two hundred thirty-six patients entered the trial. These patients had mild-to-moderate PD (stages I-III Hoehn-Yahr) and were experiencing Parkinson-emergent neurogenic ED. They were randomized to receive 100 mg sildenafil on demand 1 h before sexual activity (group 1, n ¼ 118), or similar regimen of placebo (group 2, n ¼ 118). Patients were instructed to use at least 24 doses/attempts at home. At the end of the trial, differences between sildenafil and placebo groups were significant for the IIEF erectile function (EF) score (22.6 ± 4.6 vs 14.8 ± 4.2, P ¼ 0.01), for percent Global Efficacy Question 'Yes' responses (68.1±4.6 vs 12.2±3.2, P ¼ 0.001), for SEP2 'Yes' responses (68.1±4.2 vs 32.5±2.2, P ¼ 0.003), for SEP3 'Yes' responses (75.9±5.4 vs 33.5 ± 4.4, P ¼ 0.004) and for mean EDITS score (69.8 ± 4.2 vs 13.0 ± 2.7, P ¼ 0.004). A normal EF domain score (X26) at end point was achieved by 56.9 and 8.7% of the patients in the sildenafil and placebo groups, respectively (P ¼ 0.001). Sildenafil can be considered as an effective treatment in patients with Parkinson-emergent ED.

show abstract

“…69 Double-blind, placebo-controlled, flexibledose trials of sildenafil (25,50, and 100 mg) showed that significantly more men treated with sildenafil compared with placebo for ED were satisfied with their ED treatment (defined as an EDITS Index score 450 out of 100), including 75% (93/124) compared with 30% (36/121) in the 12-week trial that initially used the EDITS (Po0.0001). 70 In a pooled analysis of six trials of 6 or 12 weeks' duration, treatment satisfaction rates were significantly higher with sildenafil compared with placebo regardless of patient age, with 70% (101/144) vs 28% (34/121) aged o65 years and 66% (45/68) versus 21% (16/77) aged X65 years satisfied with their ED treatment (Pp0.0001). 71 An open-label, prospective trial of 2816 men with ED who received sildenafil for at least 10 weeks included an optional assessment of female partner treatment satisfaction using the 5-item partner EDITS at the final visit.…”

Section: Erectile Dysfunction Treatment Satisfactionmentioning

confidence: 94%

Sildenafil citrate (Viagra) treatment for erectile dysfunction: an updated profile of response and effectiveness

Padma‐Nathan

2006

Int J Impot Res

View full text Add to dashboard Cite

In the 7 years since sildenafil citrate (VIAGRA) was introduced as the first oral phosphodiesterase type 5 inhibitor therapy for erectile dysfunction, it has been used to treat nearly 27 million men with erectile dysfunction worldwide. Patient populations with erectile dysfunction of varying etiologies and with diverse comorbidities have benefited from sildenafil treatment. This update focuses on relatively recent research that further defines the response and effectiveness profiles of sildenafil and provides additional insight into optimizing treatment. In addition to providing recent data on sildenafil efficacy and safety/tolerability, the update provides data on assessments of erection hardness, measures of psychosocial outcomes (e.g., emotional well-being and treatment satisfaction), and treatment approaches to maximize response and effectiveness (e.g., by titrating to the maximum tolerated dose). Increased understanding of the sildenafil response and effectiveness profiles and optimal sildenafil treatment are central to the appropriate management of erectile dysfunction using sildenafil.

show abstract

Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire

Cited by 99 publications

References 13 publications

Treatment satisfaction in patients with erectile dysfunction switching from prostaglandin E1 intracavernosal injection therapy to oral sildenafil citrate

Treatment satisfaction in patients with erectile dysfunction switching from prostaglandin E1 intracavernosal injection therapy to oral sildenafil citrate

Safety and efficacy of sildenafil citrate in the treatment of Parkinson-emergent erectile dysfunction: a double-blind, placebo-controlled, randomized study

Sildenafil citrate (Viagra) treatment for erectile dysfunction: an updated profile of response and effectiveness

Contact Info

Product

Resources

About